To identify therapeutic targets and prognostic markers for basal breast
cancers,
breast cancer cell lines were subjected to mass spectrometry-based profiling of
protein tyrosine phosphorylation events. This revealed that
luminal and basal
breast cancer cells exhibit distinct
tyrosine phosphorylation signatures that depend on pathway activation as well as
protein expression. Basal
breast cancer cells are characterized by elevated
tyrosine phosphorylation of Met, Lyn, EphA2,
epidermal growth factor receptor (EGFR), and FAK, and
Src family kinase (SFK) substrates such as p130Cas. SFKs exert a prominent role in these cells, phosphorylating key regulators of adhesion and migration and promoting
tyrosine phosphorylation of the
receptor tyrosine kinases EGFR and Met. Consistent with these observations, SFK inhibition attenuated cellular proliferation, survival, and motility. Basal
breast cancer cell lines exhibited differential responsiveness to small molecule inhibitors of EGFR and Met that correlated with the degree of target phosphorylation, and reflecting
kinase coactivation, inhibiting two types of activated network
kinase (e.g., EGFR and SFKs) was more effective than single agent approaches. FAK signaling enhanced both proliferation and invasion, and Lyn was identified as a proinvasive component of the network that is associated with a basal phenotype and poor prognosis in patients with
breast cancer. These studies highlight multiple
kinases and substrates for further evaluation as therapeutic targets and
biomarkers. However, they also indicate that patient stratification based on expression/activation of
drug targets, coupled with use of multi-
kinase inhibitors or combination
therapies, may be required for effective treatment of this
breast cancer subgroup.